Extending ADHD Coverage for the Entire Active Day
The next evolution in ADHD therapy needs to focus not only on drug efficacy but also on how treatment aligns with the ever-busy and demanding lives of patients, families, and caregivers.
Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company
M&A activity is going beyond big pharma acquisitions with Supernus Pharmaceuticals and Indivior Pharmaceuticals reaching a stock deal that the companies call a merger of equals. The combined company’s portfolio will have 11 commercialized products in addiction, attention-deficit hyperactivity disorder, depression, and Parkinson’s disease.
presented by
Automation Didn’t Dehumanize Care. Bad Systems Did.
We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.
The Battles We Face: ADHD From A Patient Perspective, And What Providers Should Know
Caring for patients with ADHD, or those who potentially have ADHD, extends far beyond diagnosis and prescribing.
Navigating Co-Occurring ADHD and Eating Disorders
Co-occurring ADHD and eating disorders can intensify the symptoms of each other. Impulsivity can lead to binge eating or purging and emotional dysregulation can make it challenging to cope with life’s difficulties. Addressing both ADHD and an eating disorder at the same time can best forge the path to recovery and healthy coping.
Children and Mental Health: Using Behavioral Activation to Combat the ‘Summer Slump’
It’s important to keep in mind that parents, with physician support, can beat the summer slump, particularly with planning and resources. Behavioral activation includes scheduling activities that encourage children to reconnect with environmental positive reinforcement and decrease avoidant behaviors and negative emotions.
Evernorth: 1 in 4 Adults Diagnosed with ADHD Don’t Get Treated
An Evernorth study found that in 2021, 25% of adults with ADHD did not receive any treatment, though this is a decrease from 38.5% in 2017. About 21.4% of adults with ADHD received both medication and behavioral therapy in 2021, up from 12.9% in 2017.
presented by
From Blind Spots to Better Outcomes: How SNF Data Transparency Strengthens LTSS
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.
Digital health investment opportunities in 2022
Child and adolescent mental health, palliative care and clinical AI are among opportunities that investors should consider closely this year an in the future.
Akili strikes $37.5M licensing deal for another game-based treatment
The company is licensing out technology from Australian digital health company TALi Digital to improve attention in early childhood. Akili will pay $37.5 million, including milestone payments and royalties.
After getting FDA clearance for video game therapeutic, Akili faces next level: insurance coverage
Akili Interactive, a digital health company that got FDA clearance last year for its video game as treatment for ADHD, recently brought in $160 million in funding. It plans to use the funds to ramp up coverage of its flagship treatment and to develop digital treatments for other cognitive conditions.
INVEST Pitch Perfect winner spotlight: Atentiv’s digital therapeutic for ADHD isn’t just fun and games
Judges picked Atentiv as the winning pitch at MedCity Invest’s virtual conference. The Boston-based startup is building a game to improve attention in kids with ADHD.
presented by
Closing the Quality-Affordability Gap in Workplace Mental Health
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
Akili’s long journey to build the first video game as a treatment
After years of work, Akili received FDA clearance for its video game to be used as a treatment for ADHD. CEO Eddie Martucci shared what went into that process and what’s next.
In a first, FDA clears video game for kids with ADHD
Digital health company Akili Interactive received FDA de novo clearance for its digital therapeutic, a video game intended to improve attention among kids with ADHD.
NeuroSigma wins FDA nod for first non-drug ADHD treatment
The company's cell phone-sized device delivers low-level electric stimulation to the trigeminal nerve through a patch placed on a patient's forehead.
What are the barriers and drivers for technology in mental health treatment?
Panelists at the MedCity Engage conference in San Diego agreed that a growing shortage of mental health professionals mean that technology has a key role to play in improving behavioral health treatment.
Cognoa partners with SAP to better support kids’ developmental needs
By teaming up, SAP employees will be able to use Cognoa's app to screen their children for developmental delays in language, behavior and other areas.